collection of information between 30 and 60 days after publication of this document in the **Federal Register**. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the following: Office of Management and Budget, Paperwork Reduction Project, 725 17th Street, N.W., Washington, D.C. 20503, Attn: Ms. Wendy Taylor.

Dated: July 29, 1997.

### **Bob Driscoll**,

Reports Clearance Officer.

[FR Doc. 97-20679 Filed 8-5-97; 8:45 am]

BILLING CODE 4184-01-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Administration for Children and Families

### Submission for OMB Review; Comment Request

*Title:* State Developmental Disabilities Council Annual Program Performance Report.

OMB No.: 0980-0172.

Description: Section 107 of the DD Act requires the State DD Councils of each State to prepare and transmit to the Secretary, DHHS, an annual Report for the preceding fiscal year. It is to describe the activities and resultant

accomplishments carried out with Part B funds received for the Federal fiscal year, and the general situation in the States for individuals with developmental disabilities. The information is necessary for annual technical assistance and monitoring, as well as, preparation of the Secretary's Annual Report to the President, the Congress, and the National Council on Disabilities.

Respondents: Individuals and Households; Not-for-Profit Institutions; and State, Local or Tribal Govt.

#### ANNUAL BURDEN ESTIMATES

| Instrument   | Number of respondents | Number of<br>responses<br>per respond-<br>ent | Average bur-<br>den hours<br>per response | Total<br>burden<br>hours |
|--|-----------------------|---|---|--------------------------|
| DD Council PPREstimated total annual burden hours: | 55                    | 1   | 44  | 2,240<br>2,420           |

Additional Information: Copies of the proposed collection may be obtained by writing to The Administration for Children and Families, Office of Information Services, Division of Information Resource Management Service, 370 L'Enfant Promenade, SW., Washington, DC 20447, Attn: ACF Reports Clearance Officer.

OMB Comment: OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the **Federal Register**. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the following: Office of Management and Budget, Paperwork Reduction Project, 725 17th Street, NW., Washington, DC 20503, Attn: Ms. Wendy Taylor.

Dated: July 29, 1997.

### Robert Driscoll,

Reports Clearance Officer.

[FR Doc. 97-20680 Filed 8-5-97; 8:45 am]

BILLING CODE 4184-01-M

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

### **Food and Drug Administration**

[Docket No. 95N-0309]

### Agency Information Collection Activities: Proposed Collection; Extension

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain information by the agency. Under the Paperwork Reduction Act of 1995 (the PRA), Federal agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on information collection regarding the manufacture of infant formula, including infant formula labeling,

quality control procedures, notification requirements, and recordkeeping.

**DATES:** Submit written comments on the collection of information by October 6, 1997.

ADDRESSES: Submit written comments on the collection of information to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857. All comments should be identified with the docket number found in brackets in the heading of this document.

### FOR FURTHER INFORMATION CONTACT:

Margaret R. Wolff, Office of Information Resources Management (HFA–250), Food and Drug Administration, 5600 Fishers Lane, rm. 16B–19, Rockville, MD 20857, 301–827–1223.

**SUPPLEMENTARY INFORMATION:** Under the PRA (44 U.S.C. 3501–3520), Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. "Collection of information" is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes agency requests

or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal agencies to provide a 60-day notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed collection of information listed below.

With respect to the following collection of information, FDA invites comments on: (1) Whether the proposed collection of information is necessary for the proper performance of FDA's functions, including whether the information will have practical utility; (2) the accuracy of FDA's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be

collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology.

**Infant Formula Requirements (21 CFR** 106.100, 21 CFR 106.120(b), 21 CFR 107.10(a), 21 CFR 107.20, 21 CFR 107.50(e)(2), 21 CFR 107.50(b)(3), 21 CFR 107.50(b)(4), 21 CFR 107.50(c)(3))—(OMB Control Number 0910-0256)-Extension

Statutory requirements for infant formula under the Federal Food, Drug, and Cosmetic Act (the act) are strict to protect the health of infants and include a number of reporting and recordkeeping requirements. Among other things, section 412 of the act (21 U.S.C. 350a) requires manufacturers of infant formula to establish and adhere to quality control procedures, notify FDA when a batch of infant formula that has left the manufacturer's control may be adulterated or misbranded, and keep records of distribution. FDA has issued regulations to implement the act's

requirements for infant formula in 21 CFR parts 106 and 107.

FDA also regulates the labeling of infant formula under the authority of section 403 (21 U.S.C. 343). Under the labeling regulations for infant formula in 21 CFR part 107, the label of an infant formula must include nutrient information and directions for use. The purpose of these labeling requirements is to ensure that consumers have the information they need to prepare and use infant formula appropriately.

In a notice published in the Federal **Register** of July 9, 1996 (61 FR 36154), FDA proposed changes in the infant formula regulations, including some of those listed below. The notice included revised burden estimates for the proposed changes and solicited public comment. In the interim, however, FDA is seeking an extension of OMB approval for the current regulations so that it can continue to collect information while the proposal is pending.

FDA estimates the burden of this collection of information as follows:

TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN

| 21 CFR Section                      | No. of<br>Respondents | Annual<br>Frequency per<br>Response | Total Annual<br>Responses | Hours per<br>Response | Total Hours |
|-------------------------------------|-----------------------|-------------------------------------|---------------------------|-----------------------|-------------|
| 106.120(b)<br>107.10(a)<br>107.20   | 4                     | 7                                   | 28                        | 10                    | 280         |
| 107.50(b)(3),(b)(4)<br>107.50(e)(2) | 3                     | 4                                   | 12                        | 5                     | 60          |
| Total                               |                       |                                     |                           |                       | 340         |

There are no capital costs or operating and maintenance costs associated with this collection.

TABLE 2.—ESTIMATED ANNUAL RECORDKEEPING BURDEN

| 21 CFR Section          | No. of<br>Recordkeepers | Annual<br>Frequency per<br>Recordkeeping | Total Annual<br>Records | Hours per<br>Recordkeeper | Total Hours |
|-------------------------|-------------------------|--|-------------------------|---------------------------|-------------|
| 106.100<br>107.50(c)(3) | 4                       | 10                                       | 40                      | 7,980                     | 31,920      |

There are no capital costs or operating and maintenance costs associated with this collection.

In compiling these estimates, FDA consulted its records of the number of infant formula submissions received in the past. The figures for hours per response are based on estimates from experienced persons in the agency and in industry. Because these infant formula regulations implement statutory information collection requirements, only the additional burden attributable to the regulations has been included in the estimates.

Dated: July 30, 1997.

### William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 97-20633 Filed 8-5-97; 8:45 am]

BILLING CODE 4160-01-Fst

### **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

Food and Drug Administration

[Docket No. 97N-0320]

Agency Information Collection **Activities; Submission for OMB Review; Comment Request** 

**AGENCY:** Food and Drug Administration,

HHS.

**ACTION:** Notice.